Merck wins approval for Keytruda plus chemo in first-line lung cancer setting

10 September 2018
merck_msd_rchsolutions_big

New Jersey, USA-based Merck & Co (NYSE: MRK) has won European approval for Keytruda (pembrolizumab) in combination with platinum-based chemotherapy and pemetrexed. Pemetrexed is marketed as Alimta by Eli Lilly (NYSE: LLY).

The new approval covers the first-line treatment of certain non-small cell lung cancer (NSCLC) patients.

The therapy has been shown to reduce the risk of death by more than 50% compared to pemetrexed and platinum-based chemotherapy alone.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical